Advanced Practice Providers

At the 6th Annual SONO meeting, Beth Sandy, MSN, CRNP, reviewed available treatment options for patients with identified driver mutations in non–small cell lung cancer.

Sarah Donahue, MPH, NP, AOCNP, explains the trial design of the pivotal DESTINY-Breast04 trial and discusses how the promising performance of trastuzumab deruxtecan might impact patients with unresectable or metastatic HER2-low breast cancer.

Beth Sandy, MSN, CRNP, discusses some of the challenges that may be associated with molecular testing, and how oncology nurses can help play a role in ensuring that the reports are received.

Kelley A. Rone, DNP, RN, AGNP-c, discusses the advantages associated with immunotherapy in the treatment of patients with gastrointestinal cancers.

Gabriella Magarelli, MSN, ACNP-BC, AOCNP, reflects on lessons learned caring for patients with cancer and COVID-19.

An analysis of patient-reported outcomes from the phase 3, INTRIGUE trial (NCT03673501) showed that ripretinib had a more tolerable safety profile than sunitinib in treating patients with advanced GIST tumors.

A combined analysis of 3 real-world studies assessing the use of ixazomib/lenalidomide/dexamethasone (IRd) in patients with relapsed or refractory multiple myeloma found the patient outcomes to be consistent with original phase 3 findings.

Pediatric oncology nurses and social workers routinely collaborate not only in the biopsychosocial assessment of families’ psychosocial needs and distress, but in developing interventions that can improve a patient’s and family’s quality of life while in pediatric cancer treatment and in survivorship.

Brexucabtagene autoleucel, a CAR T-cell therapy approved in 2021 for relapsed or refractory B-cell acute lymphoblastic leukemia, showed efficacious results and promising safety data at 2-year follow-up.

Ribociclib was associated with significantly favorable symptom-related quality of life scores compared with abemaciclib among women with hormone receptor–positive, HER2-negative advanced breast cancer.

Understanding various clot characteristics and bleeding risk factors can help providers carefully manage acute venous thromboembolism.

Patients receiving bevacizumab plus olaparib to treat newly diagnosed ovarian cancer experienced significantly longer time without signs of toxicity compared with placebo.

Nivolumab, whether in combination with ipilimumab or as a monotherapy, was associated with improved overall survival, progression-free survival, and melanoma-specific survival, compared with ipilimumab in advanced melanoma.

Patients with breast cancer who experience adjuvant hormone therapy (AHT)-related hot flashes and are treated for hot flashes at the beginning of therapy had worse outcomes than those who did not.

A subgroup analysis found that the addition of durvalumab to chemotherapy resulted in maintained overall survival benefit in patients with advanced biliary tract cancer, regardless of primary tumor location.

Ilene Galinsky, BSN, MSN, ANP-C, underscores effective symptom management strategies when prescribing venetoclax to patients with acute myeloid leukemia.

Laura J. Zitella, MS, RN, ACNP-BC, AOCN, presents a case study of a patient receiving chemotherapy for osteosarcoma who begins experiencing shortness of breath.

Ilene Galinsky, BSN, MSN, ANP-C, discusses the evolution of targeted therapy in acute myeloid leukemia treatment, and how venetoclax plays into the treatment paradigm.

The NCCN guidelines have been amended to include trastuzumab deruxtecan for use in patients with HER2-low metastatic breast cancer and sacituzumab govitecan for use in patients with triple-negative breast cancer or hormone receptor–positive, HER2-negative disease.

The addition of the HER2-Vaxx vaccine to chemotherapy resulted in 41.5% reduction in the risk of death compared with chemotherapy alone among patients with gastric cancers.

An updated safety and efficacy analysis of the ongoing CLL14 trial showed that venetoclax plus obinutuzumab continues to be an effective treatment for patients with chronic lymphocytic leukemia and coexisting conditions.

Data from the CheckMate 648 trial informed the FDA’s recent approval of 2 nivolumab combinations for esophageal squamous cell carcinoma. A 1-year follow-up analysis highlighted key safety and time-to-event data surrounding immune-related toxicities.

At the 2022 Supportive Care in Cancer Annual Meeting, Jeffrey Crawford, MD, highlighted the potential value of biosimilars in reducing gaps in care for the treatment of febrile neutropenia.

Utilization of specialty nurse practitioner driven teams and use of individualized pain protocols for patients admitted with vaso-occlusive pain crisis improves quality of life for patients with sickle cell disease, and decreased hospital stay times.

A study analyzing the long-term adrenal insufficiency outcomes of patients receiving immune checkpoint inhibition therapy found that secondary insufficiency was more common than primary in this patient population.

Although the CDC has put forth a strong effort to improve its opioid guidelines, many providers still feel that more can be done.

A real-world analysis showed that the proportion of women with ovarian cancer who required dose modifications or treatment discontinuations while receiving PARP inhibitors differed significantly between olaparib, niraparib, and rucaparib.

Frontline nivolumab and ipilimumab combination therapy was associated with increased 5-year survivorship in patients with metastatic non–small cell lung cancer—regardless of PD-L1 expression.